Efficacy of anti-PD-1 antibody SHR-1210 as second-line treatment in hepatocellular carcinoma patient with sorafenib resistance: A case report

RATIONALE: Hepatocellular carcinoma (HCC), one of the most common cancers worldwide, is an aggressive tumor with very poor prognosis. Regorafenib was the first agent to show a survival benefit over placebo in patients who showed progression while being treated with sorafenib, but it remains an unsat...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Hong, Yang, Xi, Zhao, Yaqin, Yi, Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531185/
https://www.ncbi.nlm.nih.gov/pubmed/31096541
http://dx.doi.org/10.1097/MD.0000000000015755

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531185/
https://www.ncbi.nlm.nih.gov/pubmed/31096541
http://dx.doi.org/10.1097/MD.0000000000015755

Ejemplares similares